

BPH ENERGY LIMITED

ACN 095 912 002

ENTITLEMENT ISSUE PROSPECTUS

This Prospectus is for:

- (a) a pro-rata non-renounceable entitlement issue of up to one (1) Share for every 25 Shares held by those Shareholders registered at the Record Date at an issue price of \$0.013 per Share to raise up to approximately \$400,000, together with one (1) free attaching Option for every Share subscribed (**Entitlement Offer**) (based on the number of Shares on issue as at the date of this Prospectus);
- (b) the purposes of cleansing a placement which comprised the issue of 115,384,615 Shares (**Placement Shares**) in the Company at the issue price of \$0.013 to raise up to \$1,500,000 (**Placement**);
- (c) up to 115,384,615 Options offered to Placement participants with one (1) free attaching option for every one (1) Placement Share subscribed under the Placement (**Placement Options**); and
- (d) the issue of up to 38,461,538 options to the Lead Manager, EverBlu Capital Pty Ltd (ACN 612 793 683), on the basis of one (1) broker option for every three (3) Placement Shares issued (**Broker Option**).

IMPORTANT NOTICE

This document is important and should be read in its entirety. If after reading this Prospectus you have any questions about the Shares being offered under this Prospectus or any other matter, then you should consult your stockbroker, accountant or other professional adviser.

The Securities offered by this Prospectus should be considered as speculative.

TABLE OF CONTENTS

CORPORATE DIRECTORY	1
1. KEY OFFER INFORMATION.....	1
2. DETAILS OF THE OFFER.....	7
3. PURPOSE AND EFFECT OF THE OFFER.....	14
4. RIGHTS AND LIABILITIES ATTACHING TO SECURITIES	17
5. RISK FACTORS	22
6. ADDITIONAL INFORMATION	33
7. DIRECTORS' AUTHORISATION	41
8. DEFINITIONS	42

IMPORTANT NOTICE

This Prospectus is dated 26 August 2022 and was lodged with the ASIC on that date. The ASIC, ASX and their respective officers take no responsibility for the contents of this Prospectus or the merits of the investment to which this Prospectus relates.

No Securities may be issued on the basis of this Prospectus later than 13 months after the date of this Prospectus.

No person is authorised to give information or to make any representation in connection with this Prospectus, which is not contained in this Prospectus. Any information or representation not so contained may not be relied on as having been authorised by the Company in connection with this Prospectus.

It is important that investors read this Prospectus in its entirety and seek professional advice where necessary. The Securities offered by this Prospectus should be considered as highly speculative.

Applications for Securities offered pursuant to this Prospectus can only be made by an original Entitlement and Acceptance Form or Shortfall Application Form.

This Prospectus is a transaction specific prospectus for an offer of continuously quoted securities (as defined in the Corporations Act) and has been prepared in accordance with section 713 of the Corporations Act. It does not contain the same level of disclosure as an initial public offering prospectus and is only required to contain information in relation to the effect of the issue of securities on a company and the rights attaching to the securities. It is not necessary to include general information in relation to all of the assets and liabilities, financial position, profits and losses or prospects of the issuing company.

Representations contained in this Prospectus are made taking into account that the Company is a disclosing entity for the purposes of the Corporations Act and certain matters are publicly available information or may reasonably be expected to be known to investors and professional advisers whom prospective investors may consult.

No Investment Advice

The information contained in this Prospectus is not financial product advice or investment advice and does not take into account your financial or investment objectives,

financial situation or particular needs (including financial or taxation issues). You should seek professional advice from your accountant, financial adviser, stockbroker, lawyer or other professional adviser before deciding to subscribe for Securities under this Prospectus to determine whether it meets your objectives, financial situation and needs.

Forward-looking statements

This Prospectus contains forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties.

These statements are based on an assessment of present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this Prospectus, are expected to take place.

Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond the control of the Company, the Directors and the Company's management.

The Company cannot and does not give any assurance that the results, performance, or achievements expressed or implied by the forward-looking statements contained in this Prospectus will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

The Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this Prospectus, except where required by law.

These forward-looking statements are subject to various risk factors that could cause the Company's actual results to differ materially from the results expressed or anticipated in these statements. These risk factors are set out in Section 5.

Overseas shareholders

This Offer does not, and is not intended to, constitute an offer in any place or jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or to issue this Prospectus.

Accordingly, the Offer is not being extended and Securities will not be issued to Shareholders with a registered address which is outside Australia or New Zealand.

For further information on overseas Shareholders please refer to Section 2.10.

Target Market Determination

In accordance with the design and distribution obligations under the Corporations Act, the Company has determined the target market for the offer of Options issued under this Prospectus. The Company will only distribute this Prospectus to those investors who fall within the target market determination (TMD) as set out on the Company's website (www.bphenergy.com.au).

By making an application under the Offer, you warrant that you have read and understood the TMD and that you fall within the target market set out in the TMD.

Financial forecasts

The Directors have considered the matters set out in ASIC Regulatory Guide 170 and believe that they do not have a reasonable basis to forecast future earnings on the basis that the operations of the Company are inherently uncertain.

Accordingly, any forecast or projection information would contain such a broad range of potential outcomes and possibilities that it is not possible to prepare a reliable best estimate forecast or projection.

Continuous Disclosure

The Company is a "disclosing entity" (as defined in section 111AC of the Corporations Act) for the purposes of section 713 of the Corporations Act and, as such, is subject to regular reporting and disclosure obligations. Specifically, like all listed companies, the Company is required to continuously disclose any information it has to the market which a reasonable person would expect to have a material effect on the price or the value of the Securities.

This Prospectus is intended to be read in conjunction with the publicly available information in relation to the Company which has been notified to ASX and does not include all of the information that would be included in a prospectus for an initial public offering of securities in an entity that is not already listed on a stock exchange. Investors should therefore have regard to the other

publicly available information in relation to the Company before making a decision whether or not to invest.

Having taken such precautions and having made such enquires as are reasonable, the Company believes that it has complied with the general and specific requirements of ASX as applicable from time to time throughout the three months before the issue of this Prospectus which required the Company to notify ASX of information about specified events or matters as they arise for the purpose of ASX making that information available to the stock market conducted by ASX.

Please refer to Section 6 for further details.

Definitions and Time

Unless the contrary intention appears or the context otherwise requires, words and phrases contained in this Prospectus have the same meaning and interpretation as given in the Corporations Act and capitalised terms have the meaning given in the Glossary in Section 8.

All references to time in this Prospectus are references to Australian Western Standard Time.

Electronic Prospectus

A copy of this Prospectus can be downloaded from the website of the Company at www.bphenergy.com.au. If you are accessing the electronic version of this Prospectus for the purpose of making an investment in the Company, you must be an Australian or New Zealand resident and must only access this Prospectus from within Australia or New Zealand.

The Corporations Act prohibits any person passing onto another person an Application Form unless it is attached to a hard copy of this Prospectus or it accompanies the complete and unaltered version of this Prospectus.

You may obtain a hard copy of this Prospectus free of charge by

contacting the Company by phone on + 61 (08) 9328 8366 during office hours or by emailing the Company at admin@bphenergy.com.au.

The Company reserves the right not to accept an Application Form from a person if it has reason to believe that when that person was given access to the electronic Application Form, it was not provided together with the electronic Prospectus and any relevant supplementary or replacement prospectus or any of those documents were incomplete or altered.

Clearing House Electronic Sub-Register System (CHES) and Issuer Sponsorship

The Company will apply to participate in CHES, for those investors who have, or wish to have, a sponsoring stockbroker. Investors who do not wish to participate through CHES will be issuer sponsored by the Company.

Electronic sub-registers mean that the Company will not be issuing certificates to investors. Instead, investors will be provided with statements (similar to a bank account statement) that set out the number of Securities issued to them under this Prospectus. The notice will also advise holders of their Holder Identification Number or Security Holder Reference Number and explain, for future reference, the sale and purchase procedures under CHES and issuer sponsorship.

Electronic sub-registers also mean ownership of securities can be transferred without having to rely upon paper documentation. Further monthly statements will be provided to holders if there have been any changes in their security holding in the Company during the preceding month.

Privacy Statement

If you complete an Application Form, you will be providing personal information to the Company. The Company collects, holds and will use that information to assess your

application, service your needs as a Shareholder and to facilitate distribution payments and corporate communications to you as a Shareholder.

The information may also be used from time to time and disclosed to persons inspecting the register, including bidders for your securities in the context of takeovers, regulatory bodies including the Australian Taxation Office, authorised securities brokers, print service providers, mail houses and the share registry.

You can access, correct and update the personal information that we hold about you. If you wish to do so, please contact the share registry at the relevant contact number set out in this Prospectus.

Collection, maintenance and disclosure of certain personal information is governed by legislation including the Privacy Act 1988 (as amended), the Corporations Act and certain rules such as the ASX Settlement Operating Rules. You should note that if you do not provide the information required on the application for Securities, the Company may not be able to accept or process your application.

Company Website

No documents or other information available on the Company's website is incorporated into this Prospectus by reference.

Enquiries

If you are in any doubt as to how to deal with any of the matters raised in this Prospectus, you should consult with your broker or legal, financial or other professional adviser without delay. Should you have any questions about the Offer or how to accept the Offer please call the Company Secretary on +61 08 9328 8366.

CORPORATE DIRECTORY

Directors

David Breeze
Chairman and Managing Director

Tony Huston
Director

Charles Maling
Director

Company Secretary

David Breeze

Registered Office

Unit 12, Level 1
114 Cedric Street
STIRLING WA 6021

Telephone: +61 08 9328 8366
Facsimile: +61 08 9328 8733

Website: www.bphenergy.com.au

Email: admin@bphenergy.com.au

ASX Code

BPH

Auditor*

HLB Mann Judd
Level 4
130 Stirling Street
PERTH WA 6000

Share Registry*

Advanced Share Registry
Services
110 Stirling Highway
NEDLANDS WA 6009

Solicitors

Steinepreis Paganin
Lawyers and Consultants
Level 4, The Read Buildings
16 Milligan Street
PERTH WA 6000

* These entities have not been involved in the preparation of this Prospectus and have not consented to being named in this Prospectus. They have been included for information purposes only.

1. KEY OFFER INFORMATION

1.1 Timetable

ASX Announcement of Offer / Resume Trading / Appendix 3B	Thursday, 18 August 2022
Anticipated Placement Settlement Date and issue of Placement Shares	Friday, 26 August 2022
Expected date of ASX Quotation of Placement Shares	Friday, 26 August 2022
Lodgement of Prospectus with the ASIC & ASX	Friday, 26 August 2022
Ex date	Wednesday, 31 August 2022
Record Date for determining Entitlements	Thursday, 1 September 2022
Entitlement Offer opening date, Prospectus sent out to Shareholders and Company announces this has been completed	Tuesday, 6 September 2022
Last day to extend the Closing Date	Monday, 12 September 2022
Closing Date for Entitlement Offer*	Thursday, 15 September 2022
Shares quoted on a deferred settlement basis	Friday, 16 September 2022
Announcement of results of issue	Tuesday, 20 September 2022
Issue date and lodgement of Appendix 2A with ASX applying for quotation of the Shares and Options	Thursday, 22 September 2022
General Meeting to approve Placement Options	Monday, 10 October 2022
Anticipated issue date of the Placement Options	Tuesday, 11 October 2022

*The Directors may extend the Closing Date by giving at least 3 Business Days' notice to ASX prior to the Closing Date. Accordingly, the date the Shares are expected to commence trading on ASX may vary.

**This timetable is indicative only and subject to change without notice. The Company reserves the right to amend any or all of these dates and times, subject to the ASC Listing Rules, Corporations Act and other applicable laws. In particular, the Company reserves the right to accept late applications under the Offer (either generally or in particular cases) and to withdraw the Offer without prior notice.

1.2 Key statistics of the Offer

	Full Subscription (\$400,000)
Entitlement Offer Price per Share	\$0.013
Entitlement Offer Ratio (based on existing Shares)	1 New Share for every 25 Shares + 1 free attaching Option (New Options) for every 1 Share subscribed for
Shares on issue prior to Placement	664,948,251
Options on issue prior to Placement	8,885,714

	Full Subscription (\$400,000)
Maximum number of Shares to be issued under the Entitlement Offer	30,769,230
Maximum number of New Options to be issued under the Entitlement Offer ¹	30,769,230
Placement Shares issued ²	115,384,615
Placement Options to be issued subject to Shareholder Approval ¹	115,384,615
Maximum number of Shares following the Entitlement Offer and Placement	811,102,096
Maximum number of Options following the Entitlement Offer and Placement ³	155,039,559
Total Shares on issue post Entitlement Offer and Placement	811,102,096

Notes:

1. Refer to Section 4.2 for the terms of the New Options and Placement Options.
2. Refer to the Company's Announcement dated 18 August 2022.
3. The total Options does not include the proposed Loyalty Options or the Broker Options. As set out at Section 1.3 below, it is the Company's intention to issue the Loyalty Options on the basis one (1) Option for every eight (8) Shares held to all Eligible Shareholders at a record date to be set in late September 2022 and the Company proposes to issue the Broker Options to EverBlu.

1.3 Background to the Entitlement Offer and Placement

As announced on 18 August 2022, the Company is conducting a non-renounceable entitlement offer and has completed a placement in order to raise up to approximately \$1,900,000 (before costs). The purpose of raising these funds is to fund the next phase of the Company's investment in Clean Hydrogen Technology, exploration and development of the Company's oil and gas investments and for general working capital purposes.

Placement

On 18 August 2022, the Company announced that it had received firm commitments from sophisticated and professional investors to raise approximately \$1,500,000 via the issue of 115,384,615 Shares at an issue price of \$0.013 per Share (**Placement Shares**), together with one (1) free attaching New Option exercisable at \$0.03 per Option and expiring on 30 September 2024 (**Placement Options**). The Placement Options will be issued subject to Shareholder approval.

The Placement Shares will be issued on the date of this Prospectus pursuant to the Company's available placement capacity under ASX Listing Rules 7.1 and 7.1A. A total of 99,742,238 Placement Shares were issued under Listing Rule 7.1 and 15,642,377 under Listing Rule 7.1A.

Placement participants are entitled to participate in the Entitlement Offer as the Placement Shares will be issued before the Record Date of the Entitlement Offer.

Further details in respect to the Placement are set out in Section 2.2 and in the ASX Announcement released by the Company on 18 August 2022.

Entitlement Offer

The Entitlement Offer is being made as a pro-rata non-renounceable entitlement offer of one (1) Share for every 25 Shares held by Eligible Shareholders registered at the Record Date at an issue price of \$0.013 per Share to raise up to \$400,000, together with one (1) free attaching Option for every one (1) Share subscribed for under the Entitlement Offer exercisable at \$0.03 per Option and expiring on 30 September 2024 (**New Options**). The purpose of the Entitlement Offer is to ensure that existing Shareholders have the opportunity to invest alongside, and on the same terms, as the Placement participants.

Further details in respect of the Entitlement Offer are set out in Section 2.1.

Loyalty Options

As announced on 18 August 2022, in recognition of the continuing support received from the Company's Shareholders, it is the Company's intention to also undertake a loyalty options issue of one (1) Option for every eight (8) Shares held to all Eligible Shareholders registered at 5:00pm (AWST) on a record date to be set by the Company in late September 2022 (**Loyalty Options**). The Loyalty Options will be issued at a subscription price of \$0.004 per Loyalty Option and will be on the same terms as the New Options to be issued under this Prospectus. Refer to Section 0 for the terms of the New Options.

The Loyalty Options will be quoted on the ASX subject to listing conditions being met and will be issued under a separate Prospectus to be lodged with ASIC.

Options entitlement to Lead Manager

The Company appointed EverBlu Capital Pty Ltd (ACN 612 793 683) (**EverBlu**) as the Lead Manager. EverBlu is entitled to receive a 6% cash fee on funds raised by EverBlu under the Placement, and one (1) broker option for every three (3) Placement Shares issued, resulting in the number of broker options to be issued being 36,461,538 (**Broker Option**). The issue of the Broker Options to EverBlu is subject to receipt of Shareholder approval. If Shareholder approval is not granted for the issue of the Broker Options, the Company will be required to pay EverBlu the cash equivalent.

Further details on the Lead Manager are available at Sections 1.7 and 6.4.

1.4 Key Risk Factors

Prospective investors should be aware that subscribing for Securities involves a number of risks and an investment in the Company should be considered as highly speculative. The future performance of the Company and the value of the Securities may be influenced by a range of factors, many of which are largely beyond the control of the Company and the Directors. The key risks associated with the Company's business, the industry in which it operates and general risks applicable to all investments in listed securities and financial markets generally are set out in Section 5.

1.5 Directors' Interests in Securities

The relevant interest of each of the Directors in the Securities of the Company as at the date of this Prospectus, together with their respective entitlement, is set out in the table below:

Director	Shares ²	Options ³	Entitlement to Shares
David Breeze	57,452,695 ¹	nil	2,298,107
Tony Huston	9,075,067	200,000 ²	363,002
Charles Maling	5,072,253	1,400,000 ³	202,890

Notes:

1. Comprising 162,832 ordinary Shares in the Company held by Mr Breeze directly, 53,494,071 ordinary Shares in the Company held by held Mr Breeze indirectly through Trandcorp Pty Ltd in its own right and as Trustee, and 3,795,792 held by Mr Breeze indirectly through Grandbridge Limited, a company of which Mr Breeze is the Managing Director.
2. Comprising 200,000 unlisted Options exercisable at \$0.20 per Option on or before 30 November 2022.
3. Comprising 200,000 unlisted Options exercisable at \$0.20 per Option on or before 30 November 2022 and 1,200,000 unlisted Options exercisable at \$0.02 per Option on or before 30 November 2024.

The Board recommends all Eligible Shareholders take up their Entitlements. The Directors intend to participate in the Entitlement Offer and take up their full Entitlement.

1.6 Details of Substantial Holders

Based on publicly available information as at the date of this Prospectus, those persons which (together with their associates) have a relevant interest in 5% or more of the Shares on issue are set out below:

Shareholder	Shares	%
Trandcorp Pty Ltd, David Breeze, Grandbridge Limited and Grandbridge Securities Limited ¹	57,452,695	8.64%
JGM Property Investments Pty Ltd, Markovic Family No.2 Pty Ltd and JLM Corporation Pty Ltd ²	34,666,682	5.21%

Notes:

1. Comprising of:
 - (a) 162,832 Shares held by David Breeze;
 - (b) 53,494,071 Shares held by Trandcorp Pty Limited; and
 - (c) 3,795,792 Shares held by Grandbridge Limited.
2. Comprising of:
 - (a) 26,277,948 Shares held by JGM Property Investments Pty Ltd;
 - (b) 3,024,077 Shares held by Markovic Family No.2 Pty Ltd; and
 - (c) 5,364,682 Shares held by JLM Corporation Pty Ltd.

The effect on the Control of the Company in the event that Shareholders do not participate in the Entitlement Offer is further described in Section 1.8 below.

1.7 Lead Manager

EverBlu was appointed as the lead manager of the Placement (**Lead Manager Mandate**). The terms of the Lead Manager Mandate and total fees payable are set out in Section 6.4.

1.8 Effect on Control

Based on current shareholding and Entitlements of Shareholders (including substantial Shareholders) as at the date of this Prospectus, regardless of the amount raised under the Entitlement Offer and Placement, no Shareholder will increase their holding, to an amount in excess of 19.9% through applying for their Entitlements.

Further as set out in Section 2.7, on the basis of the allocation policy, no person will acquire, through participation in the Shortfall Offer, a holding of Shares of, or increase their holding to, an amount in excess of 19.9% of all the Shares on issue on completion of the Offer.

Trandcorp Pty Ltd (**Trandcorp**), David Breeze (Director) and Grandbridge Limited are substantial shareholders of the Company. At the date of this Prospectus, Grandbridge Limited holds 0.02% in its own right and Trandcorp holds 8.04% in its own right and together with David Breeze's relevant interest (0.57%), the total voting power of Grandbridge Limited, Trandcorp and David Breeze (**Mr Breeze and Associates**) in the Company is 8.64% (before the Placement Shares are issued). Mr Breeze has a voting power of 32.7% in Grandbridge Limited and 100% in Trandcorp.

Mr Breeze and Associates' present relevant interest, voting power and changes under several scenarios are set out in the table below.

Event	Shares	Voting power ¹
Date of Prospectus	57,452,695	7.36%
100% subscribed	59,750,803	7.36%
75% subscribed	59,750,803	8.32%
50% subscribed	59,750,803	9.29%
Mr Breeze and Associates' Entitlement is taken up and no other shareholders subscribe under the Offer	59,750,803	11.21%

Notes:

1. Voting power calculated based on a share capital of 780,332,866 Shares as at the date of the Prospectus and including the Placement Shares issued under the Placement.

It is unlikely that no shareholders, other than Mr Breeze and Associates, take up their Entitlements under the Entitlement Offer. The Entitlements taken up and therefore the voting power of Mr Breeze and Associates will be reduced by a corresponding amount for the amount of Entitlements under the Entitlement Offer taken up by the Eligible Shareholders.

Further there will be no change to any Shareholder's voting power as a result of the issue of the New Options. Where the New Options are exercised into Shares, the voting power of the Shareholders who exercise the New Options will increase. The likelihood of the New Options being exercised is dependent on the price of Shares from time to time until the New Options expire.

1.9 Potential dilution on non-participating Shareholders

In addition to potential control impacts set out in Section 1.8, Shareholders should note that if they do not participate in the Entitlement Offer, their holdings are likely to be diluted by approximately 4.4% (as compared to their holdings and number of Shares on issue as at the date of this Prospectus).

No immediate dilution will occur as a result of the issue of the New Options under this Prospectus. However subsequent exercise of any or all of the New Options will result in dilution. Assuming all New Options offered pursuant to this Prospectus are issued and exercised into Shares, Shareholders who do not participate in the Entitlement Offer, are likely to be diluted by an aggregate of approximately 3.80% (as compared to their holdings and number of Shares on issue as at the date of the Prospectus).

For illustrative purposes, the table below shows how the dilution may impact the holdings of Shareholders:

Holder	Holding as at Record date	% at Record Date ¹	Entitlements under the Offer	Holdings if Offer not taken Up	% post Offer
Shareholder 1	10,000,000	1.28%	400,000	10,000,000	1.23%
Shareholder 2	5,000,000	0.64%	200,000	5,000,000	0.62%
Shareholder 3	1,500,000	0.19%	60,000	1,500,000	0.18%
Shareholder 4	400,000	0.05%	16,000	400,000	0.05%
Shareholder 5	50,000	0.01%	2,000	50,000	0.01%

Notes:

1. This is based on a share capital of 780,332,866 Shares as at the date of the Prospectus and including the Placement Shares issued under the Placement and assumes no Shares are issued or Options are exercised.
2. The dilutionary effect shown in the table is the maximum percentage on the assumption that those Entitlements not accepted by Eligible Shareholders are placed under the Shortfall Offer. In the event all Entitlements are not accepted and some or all of the resulting Shortfall was not subsequently placed, the dilution effect for each Shareholder not accepting their Entitlement would be a lesser percentage.

2. DETAILS OF THE OFFER

2.1 The Entitlement Offer

The Entitlement Offer is being made as a pro-rata non-renounceable entitlement issue of one (1) Share for every 25 Shares held by Eligible Shareholders registered at the Record Date at an issue price of \$0.013 per Share together with one (1) free Option for every one (1) Share subscribed for. Fractional entitlements will be rounded up to the nearest whole number.

Based on the capital structure of the Company as at the date of this Prospectus (and assuming no existing Options are exercised prior to the Record Date) approximately 30,769,230 Shares and 30,769,230 New Options may be issued under the Entitlement Offer to raise up to approximately \$400,000. No funds will be raised from the issue of the New Options.

As at the date of this Prospectus the Company has 8,885,714 Options on issue, all of which may be exercised prior to the Record Date in order to participate in the Offer. Please refer to Section 3.3 for information on the exercise price and expiry date of the Options on issue.

There is no minimum subscription to participate in the Entitlement Offer and all of the Shares offered under this Prospectus will rank equally with the Shares on issue at the date of this Prospectus. The New Options will be exercisable at \$0.03 expiring 30 September 2024 and otherwise on the terms set out in Section 4.2. Please refer to Section 4.1 for further information regarding the rights and liabilities attaching to the Shares.

The purpose of the Offer and the intended use of funds raised are set out in Section 3.

How to take up your Entitlement under the Entitlement Offer is set out in Section 2.3 below.

2.2 The Placement

2.2.1 Placement Shares

As detailed in Section 1.3 above, on 26 August 2022 the Company issued 115,384,615 Placement Shares to new sophisticated and professional investors, including high net worth individuals, family office and dedicated resource funds participants discovered through EverBlu. The Placement Shares were issued without an accompanying disclosure document under the applicable exemptions in sections 708(8) and 708(11) of the Corporations Act.

The purpose of this Prospectus is to cleanse the Placement Shares issued by the Company for the purposes of section 708A(11) of the Corporations Act, in order to remove any trading restrictions on the sale of Shares issued by the Company. Relevantly, section 708A(11) of the Corporations Act provides that a sale offer does not need disclosure to investors if:

- (a) the relevant securities are in a class of securities that are quoted securities of the body; and
- (b) either:

- (i) a prospectus is lodged with the ASIC on or after the day on which the relevant securities were issued but before the day on which the sale offer is made; or
 - (ii) a prospectus is lodged with ASIC before the day on which the relevant securities are issued and offers of securities that have been made under the prospectus are still open for acceptance on the day on which the relevant securities were issued; and
- (c) the prospectus is for an offer of securities issued by the body that are in the same class of securities as the relevant securities.

2.2.2 Placement Options

The Company is also issuing 115,384,615 Placement Options under the Placement.

Under this Prospectus, the Company will issue the Placement Options to allow the Placement Options, and Shares issued on the exercise of any of the Placement Options, to be on-sold within 12 months of their issue without a disclosure document or 'cleansing statement' being issued for those Placement Options or Shares, that otherwise would be required under the Corporations Act to on-sell those Placement Options or Shares within 12 months of their issue.

No funds will be raised from the issue of Placement Options as they are being issued for nil consideration. The issue of the Placement Options is subject to the receipt of Shareholder approval at the General Meeting of the Company to be convened as soon as possible.

If Shareholder approval is not received, the Placement Options will not be issued.

If you participated in the Placement then your application for Placement Options can be accessed at www.bphenergy.com.au/. **Please read the instructions carefully.**

2.3 What Eligible Shareholders may do

The number of Securities to which Eligible Shareholders are entitled is shown on the personalised Entitlement and Acceptance Form which accompanies this Prospectus or can be accessed at www.bphenergy.com.au/.

Eligible Shareholders may choose any of the options set out in the table below.

Option	Key Considerations	For more information
Take up all of your Entitlement	<ul style="list-style-type: none"> • Should you wish to accept all of your Entitlement, then your application for Securities under this Prospectus must be made by following the instructions on the personalised Entitlement and Acceptance Form which can be accessed at www.bphenergy.com.au/. Please read the instructions carefully. • Payment can be made by the methods set out in Section 2.4. As set out in Section 2.4, if you pay by BPAY you do not need to return the Entitlement and Acceptance Form. 	Section 2.4 and Section 2.5.
Take up all of your Entitlement and	<ul style="list-style-type: none"> • Should you wish to accept all of your Entitlement and apply for Shortfall Securities, then your application for 	Sections 2.4, 2.5 and 2.7.

Option	Key Considerations	For more information
also apply for Shortfall Securities	<p>your Entitlement and additional Shortfall Securities under this Prospectus must be made by following the instructions on your personalised Entitlement and Acceptance Form.</p> <p>Please read the instructions carefully.</p> <ul style="list-style-type: none"> • Payment can be made by the methods set out in Section 2.4. Payment should be made for your Entitlement and the amount of the Shortfall for which you are applying. • If you apply for Shortfall Securities beyond your Entitlement you are deemed to have accepted your Entitlement in full. You should note that the allocation of Shortfall Securities is at the Company's absolute discretion as per the allocation policy set out in Section 2.7. Accordingly, your application for additional Shortfall Securities may be scaled-back. • The Company's decision on the number of Shortfall Securities to be allocated to you will be final. 	
Take up a proportion of your Entitlement and allow the balance to lapse	<ul style="list-style-type: none"> • Should you wish to take up only part of your Entitlement and allow the balance to lapse, your application must be made by completing the personalized Entitlement and Acceptance Form for the number of Securities you wish to take up and making payment using the methods set out in Section 2.4 below. As set out in Section 2.4, if you pay by BPAY, you do not need to return the Entitlement and Acceptance Form. • If you take no further action, the balance of your Entitlement will lapse and you will have forfeited any potential benefit to be gained from taking up that part of your Entitlement. 	Section 2.4 and Section 2.5
Allow all or part of your Entitlement to lapse	<ul style="list-style-type: none"> • If you do not wish to accept any part of your Entitlement, you are not obliged to do anything. If you do not take up your Entitlement by the Closing Date, the Offer to you will lapse. 	N/A

The Entitlement Offer is non-renounceable. Accordingly, a Shareholder may not sell or transfer all or part of their Entitlement.

2.4 Payment options

(a) By BPAY®

For payment by BPAY®, please follow the instructions on the Entitlement and Acceptance Form. You can only make a payment via BPAY® if you are the holder of an account with an Australian financial institution that supports BPAY® transactions. Please note that should you choose to pay by BPAY®:

- (i) you do not need to submit the Entitlement and Acceptance Form but are taken to have made the declarations on that Entitlement and Acceptance Form;

- (ii) if you do not pay for your Entitlement in full, you are deemed to have taken up your Entitlement in respect of such whole number of Shares which is covered in full by your Application monies; and
- (iii) if you pay more than is required to subscribe for your Entitlement, you will be taken to have applied for Shortfall Securities (if any) under the Shortfall Offer, to the extent of the excess.

You should be aware that your own financial institution may implement earlier cut-off times with regard to electronic payment, and you should therefore take this into consideration when making payment. **It is your responsibility to ensure that funds submitted through BPAY® are received by 5:00pm (WST) on the Closing Date. The Company shall not be responsible for any delay in the receipt of the BPAY® payment.**

Guidance where you have more than one CRN (Shareholding of Shares)

If you have more than one shareholding of Shares and consequently receive more than one Entitlement and Acceptance Form, when taking up your Entitlement in respect of one of those Shareholdings only use the CRN specific to that Shareholding as set out in the applicable Entitlement and Acceptance Form. **Do not use the same CRN for more than one of your Shareholdings.** This can result in your Application monies being applied to your Entitlement in respect of only one of your Shareholdings (with the result that any Application in respect of your remaining Shareholdings will not be valid).

(b) By Electronic Funds Transfer (overseas applicants)

For payment by Electronic Funds Transfer (**EFT**) for overseas Eligible Shareholders, please follow the instructions on the Entitlement and Acceptance Form. You can only make a payment via EFT if you are the holder of an account that supports EFT transactions to an Australian bank account. Please note that should you choose to pay by EFT:

- (i) you do not need to submit the Entitlement and Acceptance Form but are taken to have made the declarations on that Entitlement and Acceptance Form;
- (ii) if you do not pay for your Entitlement in full, you are deemed to have taken up your Entitlement in respect of such whole number of Shares which is covered in full by your Application monies; and
- (iii) if you pay more than is required to subscribe for your Entitlement, you will be taken to have applied for Shortfall Securities (if any) under the Shortfall Offer, to the extent of the excess.

(c) Other payment Methods and Refunds

Payment will only be accepted by BPAY® or EFT and receipts for payment will not be issued. Cash, bank drafts and cheques will not be accepted.

2.5 Implications of an acceptance

Returning a completed Entitlement and Acceptance Form or paying any Application monies by BPAY® or EFT will be taken to constitute a representation by you that:

- (a) you have received a copy of this Prospectus and the accompanying Entitlement and Acceptance Form, and read them both in their entirety;
- (b) you acknowledge that once the Entitlement and Acceptance Form is returned, or a BPAY® or EFT payment instruction is given in relation to any Application monies, the application may not be varied or withdrawn except as required by law.

2.6 Minimum subscription

There is no minimum subscription.

2.7 Shortfall Offer

Any Entitlement not taken up pursuant to the Entitlement Offer will form the Shortfall Offer (**Shortfall Securities**). The Shortfall Offer is a separate offer made pursuant to this Prospectus and will remain open for up to three months following the Closing Date. The issue price for each Share to be issued under the Shortfall Offer shall be \$0.013 per Share being the price at which Shares have been offered under the Entitlement Offer.

If you do not wish to take up any part of your Entitlement you are not required to take any action. That part of your Entitlement not taken up will form part of the Shortfall Offer and potentially be allocated to other Eligible Shareholders or other third parties as part of the Shortfall Offer. The Shortfall Offer will only be available where there is a Shortfall between applications received from Eligible Shareholders and the number of Shares proposed to be issued under the Offer.

Related Parties, including Directors, are not entitled to participate in the Shortfall Offer.

The Board presently intends to allocate Shortfall Securities as follows:

- (a) to Eligible Shareholders who apply for an excess of their full Entitlement, so long as the issue of Shortfall Securities to that Eligible Shareholder would not take their voting power to in excess of 19.99%; and then
- (b) to other parties identified by the Directors, which may include parties who are not currently Shareholders.

Depending on the level of demand for Shortfall, the Company may also engage with EverBlu to seek to place the Shortfall Shares.

The Company reserves the right to issue an Eligible Shareholder a lesser number of Shortfall Securities than applied for or no Shortfall Securities at all. However, the Directors do not intend to refuse an application for Shortfall Securities from Eligible Shareholders other than in circumstances of oversubscription or where acceptance may result in a breach of the Corporations Act. If the number of Shortfall Securities applied for by Eligible Shareholders exceeds the total Shortfall, the Shortfall Securities will be allocated among applying Eligible Shareholders proportionate to their existing holdings.

All decisions regarding the allocation of Shortfall Securities will be made by the Directors and will be final and binding on all applicants under the Shortfall Offer; as such there is no guarantee that any Shortfall Securities applied for will be issued to Eligible Shareholders.

The Company will have no liability to any Applicant who receives less than the number of Shortfall Securities they applied for under the Shortfall Offer. If the Company scales back any applications for Shortfall Securities under the Shortfall Offer any Application monies will be returned (without interest) as soon as practicable.

2.8 ASX listing

Application for Official Quotation of the Shares offered pursuant to this Prospectus will be made in accordance with the timetable set out at Section 1. If ASX does not grant Official Quotation of the Shares offered pursuant to this Prospectus before the expiration of three months after the date of issue of the Prospectus, (or such period as varied by the ASIC), the Company will not issue any Shares and will repay all Application monies for the Shares within the time prescribed under the Corporations Act, without interest.

The fact that ASX may grant Official Quotation to the Shares is not to be taken in any way as an indication of the merits of the Company or the Shares now offered for subscription.

The Company will also apply for Official Quotation of the New Options issued pursuant to this Prospectus.

2.9 Issue of Securities

Securities issued pursuant to the Entitlement Offer and Placement will be issued in accordance with the ASX Listing Rules and timetable set out at Section 1.

Securities issued pursuant to the Shortfall Offer will be issued on a progressive basis. Where the number of Securities issued is less than the number applied for, or where no issue is made surplus Application monies will be refunded without any interest to the Applicant as soon as practicable after the closing date of the Shortfall Offer.

Pending the issue of the Securities or payment of refunds pursuant to this Prospectus, all Application monies will be held by the Company in trust for the Applicants in a separate bank account as required by the Corporations Act. The Company, however, will be entitled to retain all interest that accrues on the bank account and each Applicant waives the right to claim interest.

Holding statements for Securities issued under the Entitlement Offer will be mailed as soon as practicable after the issue of Securities and for Shortfall Securities issued under the Shortfall Offer as soon as practicable after their issue.

2.10 Overseas shareholders

The Entitlement Offer does not, and is not intended to, constitute an offer in any place or jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or to issue this Prospectus. In particular, the new Shares may not be offered or sold in any country outside Australia, except to the extent permitted below.

New Zealand

The Securities are not being offered to the public within New Zealand other than to existing shareholders of the Company with registered addresses in New Zealand to whom the offer of these securities is being made in reliance on the transitional provisions of the Financial Markets Conduct Act 2013 (New Zealand) and the

Financial Markets Conduct (Incidental Offers) Exemption Notice 2021 (New Zealand).

This Prospectus has been prepared in compliance with Australian law and has not been registered, filed with or approved by any New Zealand regulatory authority. This document is not a product disclosure statement under New Zealand law and is not required to, and may not, contain all the information that a product disclosure statement under New Zealand law is required to contain.

Nominees and custodians

Nominees and custodians may not submit an Entitlement and Acceptance Form on behalf of any Shareholder resident outside Australia or New Zealand without the prior consent of the Company, taking into account relevant securities law restrictions. Return of a duly completed Entitlement and Acceptance Form will be taken by the Company to constitute a representation that there has been no breach of those regulations.

2.11 Enquiries

Any questions concerning the Offer should be directed to the Company Secretary, David Breeze, on +61 08 9328 8366.

3. PURPOSE AND EFFECT OF THE OFFER

3.1 Purpose of the Offer

The purpose of the Entitlement Offer is to raise up to \$400,000 before costs. The total funds raised from the Placement and the Entitlement Offer will be \$1,900,000 (before costs) in aggregate.

The funds raised from the Placement and Entitlement Offer are intended to be applied in accordance with the table set out below:

Item	Proceeds of the Offer	Full Subscription (\$)	%
1.	Further investment into Clean Hydrogen Technology	900,000	47%
2.	Funding for exploration and development of the Company's existing oil and gas investments	680,000	36%
3.	General working capital including the expenses of the Placement and Entitlement Offer	320,000	17%
	Total	\$1,900,000	100%

Notes:

1. The above table is a statement of current intentions as of the date of this Notice. As with any budget, intervening events and new circumstances have the potential to affect the manner in which the funds are ultimately applied. The Board reserves the right to alter the way funds are applied on this basis.
2. Refer to Section 6.8 for further details relating to the estimated expenses of the Offer and Placement. This amount includes fees payable to EverBlu as consideration for EverBlu providing the Lead Manager services to the Company.

3.2 Effect of the Entitlement Offer and the Placement

The principal effect of the Entitlement Offer and Placement, assuming all Entitlements are accepted and the completion of the Placement, (and no Shares are issued including on exercise or conversion of other Securities on issue prior to the Record Date), will be to:

- (a) increase the cash reserves by \$1,900,000 (before deducting the estimated expenses of the Offer) immediately after completion of the Entitlement Offer and Placement; and
- (b) increase the number of Shares on issue to 811,102,096 Shares following the Entitlement Offer and the issue of the Placement Shares; and
- (c) increase the number of Options on issue to 155,039,559 Options following the Entitlement Offer and the issue of the Placement Options.

3.3 Pro-forma balance sheet

The unaudited balance sheet as at 30 June 2022 and the unaudited pro-forma balance sheet as at 30 June 2022 shown below have been prepared on the basis of the accounting policies normally adopted by the Company and reflect the changes to its financial position.

The pro-forma balance sheet has been prepared assuming all Entitlements are accepted, no Options or convertible securities are exercised prior to the Record Date and including expenses of the Placement.

The pro-forma balance sheet has been prepared to provide investors with information on the assets and liabilities of the Company and pro-forma assets and liabilities of the Company as noted below. The historical and pro-forma financial information is presented in an abbreviated form, insofar as it does not include all of the disclosures required by Australian Accounting Standards applicable to annual financial statements.

	UNAUDITED (\$) 30 June 2022	PROFORMA (\$) 30 June 2022
CURRENT ASSETS		
Cash and cash equivalents	2,894,998	4,648,737
Trade and other receivables	136,708	136,708
Financial assets	22,222	22,222
TOTAL CURRENT ASSETS	3,053,928	4,807,667
NON-CURRENT ASSETS		
Financial assets	8,192,967	8,192,967
Investments in associates	3,941,702	3,941,702
Other non-current assets	20,000	20,000
TOTAL NON-CURRENT ASSETS	12,154,669	12,154,669
TOTAL ASSETS	15,208,597	16,962,336
CURRENT LIABILITIES		
Trade and other payables	803,993	803,993
Financial liabilities	104,817	104,817
TOTAL CURRENT LIABILITIES	908,750	908,750
TOTAL LIABILITIES	908,750	908,750
NET ASSETS	14,299,847	16,053,586
EQUITY		
Issued capital	58,844,602	60,598,341
Reserves	1,105,671	1,105,671
Accumulated losses	(45,489,370)	(45,489,370)
Non-controlling interest	(161,056)	(161,056)
TOTAL EQUITY	14,299,847	16,053,586

Notes

1. The unaudited pro-forma assumes all Entitlements are accepted.
2. Refer to Section 6.8 of this Prospectus for further details relating to the estimated expenses of the Offer.

3.4 Effect on capital structure

The effect of the Entitlement Offer and the Placement on the capital structure of the Company, assuming all Entitlements are accepted, and no Shares are issued including on exercise or conversion of other Securities on issue prior to the Record Date, is set out below.

Shares

	Number
Shares on issue as at the date of this Prospectus	664,948,251
Issued under the Placement	115,384,615
Issued under the Entitlement Offer	30,769,230
Total Shares on completion of the Entitlement Offer	811,102,096

Options

	Number
Options currently on issue:	
Unlisted Options, exercisable at \$0.20 each on or before 30 November 2022	400,000
Unlisted Options, exercisable at \$0.02 each on or before 30 November 2024	1,200,000
Unlisted Options, exercisable at \$0.26 each on or before 8 February 2023	7,285,714
Options issued under the Offer	
New Options issued under the Placement, exercisable at \$0.03 on or before 30 September 2024	115,384,615
New Options issued under the Entitlement Offer exercisable at \$0.03 on or before 30 September 2024	30,769,230
Total Options on issue after completion of the Placement and Entitlement Offer	155,039,559

The capital structure on a fully diluted basis as at the date of this Prospectus would be 789,218,580 Shares (including the Placement Shares) and on completion of the Entitlement Offer (assuming all Entitlements are accepted would be 966,141,655 Shares.

4. RIGHTS AND LIABILITIES ATTACHING TO SECURITIES

4.1 Rights and liabilities attaching to Shares

The following is a summary of the more significant rights and liabilities attaching to the Shares being offered pursuant to this Prospectus. This summary is not exhaustive and does not constitute a definitive statement of the rights and liabilities of Shareholders. To obtain such a statement, persons should seek independent legal advice.

Full details of the rights and liabilities attaching to Shares are set out in the Constitution, a copy of which is available for inspection at the Company's registered office during normal business hours.

(a) General meetings

Shareholders are entitled to be present in person, or by proxy, attorney or representative to attend and vote at general meetings of the Company.

Shareholders may requisition meetings in accordance with section 249D of the Corporations Act and the Constitution of the Company.

(b) Voting rights

Subject to any rights or restrictions for the time being attached to any class or classes of shares, at general meetings of shareholders or classes of shareholders:

- (i) each Shareholder entitled to vote may vote in person or by proxy, attorney or representative;
- (ii) on a show of hands, every person present who is a Shareholder or a proxy, attorney or representative of a Shareholder has one vote; and
- (iii) on a poll, every person present who is a Shareholder or a proxy, attorney or representative of a Shareholder shall, in respect of each fully paid Share held by him, or in respect of which he is appointed a proxy, attorney or representative, have one vote for each Share held, but in respect of partly paid shares shall have such number of votes as bears the same proportion to the total of such Shares registered in the Shareholder's name as the amount paid (not credited) bears to the total amounts paid and payable (excluding amounts credited).

(c) Dividend rights

Subject to the rights of any preference Shareholders and to the rights of the holders of any shares created or raised under any special arrangement as to dividend, the Directors may from time to time declare a dividend to be paid to the Shareholders entitled to the dividend which shall be payable on all Shares according to the proportion that the amount paid (excluding amounts credited) in respect of such Shares.

The Directors may from time to time pay to the Shareholders any interim dividends as they may determine. No dividend shall carry interest as against the Company. The Directors may set aside out of the profits of the Company any amounts that they may determine as reserves, to be

applied at the discretion of the Directors, for any purpose for which the profits of the Company may be properly applied.

Subject to the ASX Listing Rules and the Corporations Act, the Company may, by resolution of the Directors, implement a dividend reinvestment plan on such terms and conditions as the Directors think fit and which provides for any dividend which the Directors may declare from time to time payable on Shares which are participating Shares in the dividend reinvestment plan, less any amount which the Company shall either pursuant to the Constitution or any law be entitled or obliged to retain, be applied by the Company to the payment of the subscription price of Shares.

(d) **Winding-up**

If the Company is wound up, the liquidator may, with the authority of a special resolution, divide among the Shareholders in kind the whole or any part of the property of the Company, and may for that purpose set such value as he considers fair upon any property to be so divided, and may determine how the division is to be carried out as between the Shareholders or different classes of Shareholders.

The liquidator may, with the authority of a special resolution, vest the whole or any part of any such property in trustees upon such trusts for the benefit of the contributories as the liquidator thinks fit, but so that no Shareholder is compelled to accept any shares or other securities in respect of which there is any liability.

(e) **Shareholder liability**

As the Shares issued will be fully paid shares, they will not be subject to any calls for money by the Directors and will therefore not become liable for forfeiture.

(f) **Transfer of shares**

Generally, shares in the Company are freely transferable, subject to formal requirements, the registration of the transfer not resulting in a contravention of or failure to observe the provisions of a law of Australia and the transfer not being in breach of the Corporations Act and the ASX Listing Rules.

(g) **Future increase in capital**

The issue of any new Shares is under the control of the Directors of the Company. Subject to restrictions on the issue or grant of securities contained in the ASX Listing Rules, the Constitution and the Corporations Act (and without affecting any special right previously conferred on the holder of an existing share or class of shares), the Directors may issue Shares as they shall, in their absolute discretion, determine.

(h) **Variation of rights**

Under section 246B of the Corporations Act, the Company may, with the sanction of a special resolution passed at a meeting of Shareholders vary or abrogate the rights attaching to Shares.

If at any time the share capital is divided into different classes of shares, the rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class), whether or not the Company is being wound up, may be varied or abrogated with the consent in writing of the holders of three quarters of the issued shares of that class, or if authorised by a special resolution passed at a separate meeting of the holders of the shares of that class.

(i) **Alteration of constitution**

In accordance with the Corporations Act, the Constitution can only be amended by a special resolution passed by at least three quarters of Shareholders present and voting at the general meeting. In addition, at least 28 days written notice specifying the intention to propose the resolution as a special resolution must be given.

4.2 Terms of New Options and Placement Options

(a) **Entitlement**

Each Option entitles the holder to subscribe for one (1) Share upon exercise of the Option.

(b) **Exercise Price**

Subject to paragraph (i), the amount payable upon exercise of each Option will be \$0.03 (**Exercise Price**).

(c) **Expiry Date**

Each Option will expire at 5:00pm (WST) on 30 September 2024 (**Expiry Date**). An Option not exercised before the Expiry Date will automatically lapse on the Expiry Date.

(d) **Exercise Period**

The Options are exercisable at any time on or prior to the Expiry Date (**Exercise Period**).

(e) **Notice of Exercise**

The Options may be exercised during the Exercise Period by notice in writing to the Company in the manner specified on the Option certificate (**Notice of Exercise**) and payment of the Exercise Price for each Option being exercised in Australian currency by electronic funds transfer or other means of payment acceptable to the Company.

(f) **Exercise Date**

A Notice of Exercise is only effective on and from the later of the date of receipt of the Notice of Exercise and the date of receipt of the payment of the Exercise Price for each Option being exercised in cleared funds (**Exercise Date**).

(g) **Timing of issue of Shares on exercise**

Within 5 Business Days after the Exercise Date, the Company will:

- (i) issue the number of Shares required under these terms and conditions in respect of the number of Options specified in the Notice of Exercise and for which cleared funds have been received by the Company;
- (ii) if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and
- (iii) if admitted to the official list of ASX at the time, apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options.

If a notice delivered under (g)(ii) for any reason is not effective to ensure that an offer for sale of the Shares does not require disclosure to investors, the Company must, no later than 20 Business Days after becoming aware of such notice being ineffective, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors.

(h) **Shares issued on exercise**

Shares issued on exercise of the Options rank equally with the then issued shares of the Company.

(i) **Reconstruction of capital**

If at any time the issued capital of the Company is reconstructed, all rights of an Optionholder are to be changed in a manner consistent with the Corporations Act and the ASX Listing Rules at the time of the reconstruction.

(j) **Participation in new issues**

There are no participation rights or entitlements inherent in the Options and holders will not be entitled to participate in new issues of capital offered to Shareholders during the currency of the Options without exercising the Options.

(k) **Change in exercise price**

A Option does not confer the right to a change in Exercise Price or a change in the number of underlying securities over which the Option can be exercised.

(l) **Transferability**

The Options are transferable subject to any restriction or escrow arrangements imposed by ASX or under applicable Australian securities laws.

5. RISK FACTORS

5.1 General

The Shares offered under this Prospectus are considered highly speculative. An investment in the Company is not risk free and the Directors strongly recommend potential investors to consider the risk factors described below, together with information contained elsewhere in this Prospectus and to consult their professional advisers before deciding whether to apply for Shares pursuant to this Prospectus.

There are specific risks which relate directly to the Company's business. In addition, there are other general risks, many of which are largely beyond the control of the Company and the Directors. The risks identified in this section, or other risk factors, may have a material impact on the financial performance of the Company and the market price of the Shares.

The following is not intended to be an exhaustive list of the risk factors to which the Company is exposed.

5.2 Company specific

Risk	Description
Going Concern Risk	<p>The Company's audit reviewed financial report for the Half-Year period ending 31 December 2021 (Half-Year Report) includes a note to the financial statements on the financial condition of the Company and the existence of a material uncertainty about the Company's ability to continue as a going concern. Notwithstanding the 'going concern' qualification included in the financial report, the Directors have stated that they have reviewed their expenditure and commitments and have implemented methods of costs reduction. The Directors are satisfied that, the going concern basis of preparation is appropriate. Future events or conditions may cause the Company to cease to continue as a going concern.</p> <p>The Company incurred a net loss before tax for the period ending 31 December 2021 of \$305,316 and has a working capital surplus of \$6,842,455 as at 31 December 2021.</p> <p>The Directors have prepared cash flow forecasts, including potential capital raisings, which indicate that the consolidated entity should have sufficient cash flows for a period of at least 12 months from the date of the Half-Year Report. Based on the cash flow forecasts, including directors voluntarily suspending cash payments for their director fees, the directors are satisfied that, the going concern basis of preparation is appropriate. The Half-Year Report has therefore been prepared on a going concern basis, which assumes continuity of normal business activities and the realisation of assets and the settlement of liabilities in the ordinary course of business.</p> <p>Notwithstanding the 'going concern' note, the Directors believe that upon the successful completion of the Offer, the Company will have sufficient funds to adequately meet the Company's current commitments and short-term working capital requirements. However, it is highly likely that further funding will be required to meet the medium to long-term working capital costs of the Company.</p> <p>Should the consolidated entity not be successful in raising additional funds through the issue of new equity, should the need arise there is a material uncertainty that may cast significant doubt as to whether or not the consolidated entity will be able to continue as a going concern and therefore, whether it will realise its assets and discharge its liabilities as and when they fall due and in the normal course of business and at the amounts stated in the financial report. The financial statements do not include any adjustments relative to the recoverability and</p>

Risk	Description
	classification of recorded asset amounts or, to the amounts and classification of liabilities that might be necessary should the entity not continue as a going concern.
Additional Requirements for Capital	Additional funding may be required in the event future costs exceed the Company's estimates and to effectively implement its business and operations plans in the future, to take advantage of opportunities for acquisitions, joint ventures or other business opportunities, and to meet any unanticipated liabilities or expenses which the Company may incur.
Potential dilution for	<p>Upon implementation of the Offer, assuming all Entitlements are accepted, the Placement is completed and no other Shares are issued on exercise or conversion of Options prior to the Record Date, the number of Shares in the Company will increase from 664,948,251 Shares to 811,102,096 Shares and the number of Options in the Company will increase from 8,885,714 to 155,039,559. This means that immediately after the Offer, each Share will represent a lower proportion of ownership in the Company.</p> <p>No immediate dilution will occur as a result of the issue of New Options under this Prospectus. However subsequent exercise of any or all of the New Options will result in dilution.</p> <p>It is not possible to predict what the value of the Company, a Share or an Option will be following the completion of the Offer being implemented and the Directors do not make any representation as to such matters.</p>
Nature of the Company's existing investments	<p>The Company's existing investments as at 31 December 2021 include its equity investment of 36.1% in Advent Energy Limited with a carrying value of \$4,250,000, a 20% interest in Molecular Discovery Systems with a carrying value of \$350,819 and a 17.5% interest in Cortical Dynamics Ltd.</p> <p><i>Investee Advent Energy Limited</i></p> <p>In light of the recent media coverage surrounding the former Prime Minister Scott Morrison, the Company is currently undertaking a full review of its options, including potential for legal channels as part of its strategy to protect Shareholder value.</p> <p>On 16 December 2021 BPH advised ASX that the then Prime Minister of Australia, Scott Morrison, had announced that the Federal Government would refuse the PEP 11 Joint Venture's application to extend the PEP 11 Permit for gas exploration in the offshore Sydney Basin. Permit participants Advent and Bounty Oil & Gas NL (Bounty) (ASX: BUY) received official notification of refusal from National Offshore Petroleum Title Authority (NOPTA).</p> <p>Advent Energy Limited (Advent) has two applications with NOPTA in relation to the suspension and extension of the PEP11 Permit. The first application was lodged in December 2019 (Joint Venture Application) and the second application was lodged in February 2021. NOPTA issued a notice of intention to refuse the January 2020 Joint Venture Application which was lodged based on Force Majeure. The Joint Venture Application is the only application which is the subject of the NOPTA notice. The second application was made under a COVID application process and was accepted but not dealt with, pending an outcome on the Joint Venture Application submitted in December 2019. NOPTA is seeking additional information from Advent in respect of this application.</p> <p>Under the provisions of the <i>Offshore Petroleum and Greenhouse Gas Storage Act 2006</i>, the PEP 11 Permit will continue until relevant decisions are made.</p> <p>On 30 March 2022, BPH and Bounty, as the PEP 11 Joint Venture, announced to ASX that they had been given notice by NOPTA that NOPTA has refused the Joint Venture Application initially submitted on 24 December 2019 for a secondary work program variation and a 24-</p>

Risk	Description
	<p>month suspension of the Permit Year 4 Work Program Commitment and the corresponding 24-month extension of the Permit term.</p> <p>Advent Energy Limited's 100% subsidiary, Asset Energy Pty Ltd has lodged an appeal in the Federal Court of Australia as operator for and on behalf of the PEP11 Joint Venture partners, Bounty and Gas NL (ASX:BUY).</p> <p>Asset Energy Pty Ltd, has applied to the Federal Court pursuant to section 5 of the Administrative Decisions (Judicial Review) Act 1977 (Cth) and section 39B of the Judiciary Act 1903 (Cth), to review the decision of the Commonwealth New South Wales Offshore Petroleum Joint Authority (Joint Authority), (constituted under section 56 of the Offshore Petroleum and Greenhouse Gas Storage Act 2006 (Cth) (Act)), to refuse to vary and suspend the conditions for, and the term of, the PEP 11 Permit, pursuant to section 264(2) and 265 of the Act. On 11 August 2022 the Federal Court of Australia made discovery orders in respect of this application and set a hearing date for 15 March 2023.</p> <p><i>Clean Carbon</i></p> <p>BPH's Shareholders approved an investment in a hydrogen technology company, Clean Hydrogen Technologies Corporation (Clean Carbon at a Shareholders' meeting held on 21 June 2022.</p> <p>BPH and Advent (together, the Purchasers) entered into a Term Sheet with Clean Carbon, pursuant to which the Purchasers agreed to subscribe for fully paid shares in Clean Carbon (Subscription Shares), representing a total of 10% of the total issued share capital of Clean Carbon after the issue of the Subscription Shares (Subscription Shares Tranche 1). The Subscription Shares Tranche 1 were issued by Clean Carbon under a Loan Conversion Agreement dated 25 July 2022 by the payment of US\$535,996 by BPH in August 2022, which was net of loans, accrued interest and deposits owed to the Purchasers by Clean Carbon. A corresponding set off was recorded in BPH's receivable from Advent such that BPH and Advent recorded an 80% / 20% share respectively of their 10% shareholding in Clean Carbon.</p> <p><i>Taranaki</i></p> <p>Advent's 100% subsidiary, Aotearoa Offshore Ltd NZ (AOLNZ), has the right to acquire a 30% participating interest in Petroleum Exploration Permits (PEP) 57075, 60092 and 60093 covering an area of 5,180 km² in the Taranaki Basin from OMV New Zealand Limited (OMV NZ).</p> <p>The three permits are governed by individual (but identical) Joint Venture Operating Agreements (JVOA's) and, as such, each intersects in the same fashion with the Farm Out Agreement (FOA). The FOA covers all three permits. Mitsui E&P withdrew from the PEP 60092 and PEP 60093 JVOA's in April 2021 with OMV NZ being assigned their 30% participating interest. Following this assignment, the joint venture for PEP 57075, 60092 and 60093 consisted of OMV NZ with a 70% participating interest and Sapura OMV Upstream (NZ) SDN BHD having a 30% participating interest (Joint Venture).</p> <p>The FOA is considered to be a positive development for Advent and its key shareholder, BPH, as it provides a significant new project for Advent which enables it to diversify beyond its current oil and gas portfolio assets.</p> <p>If the Conditions Precedent are not satisfied within 6 months of signing either party may terminate the FOA and the agreement will cease to be of any effect. The FOA was executed on 24 December 2021, meaning this 6 month period expired on 24 June 2022. No action is required or will be taken from either Advent or OMV NZ given both parties intent to proceed and have AOLNZ on permit Titles pending the Ministry of Business, Innovation and Employment's ongoing process.</p> <p><i>Patagonia Genetics</i></p>

Risk	Description
	<p>As announced by the Company on 19 May 2022, its investee Patagonia Genetics Pty Ltd ceased operations and was unable to secure licences to undertake its operations and would be initiating a winding up application. The Company has reflected a loss within its financial reports for the financial period ending 30 June 2020 and 30 June 2021 of \$250,000.</p> <p>The Company can make no representations that any of the above projects will be successful, that the Company's development milestones will be achieved or that it will develop products that are commercially exploitable.</p> <p>Further, the Company's success depends, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing the proprietary rights of third parties. Because the patent positions of biotechnology companies can be highly uncertain and frequently involve complex legal and scientific evaluation, neither the breadth of claims allowed in medical device patents, nor their enforceability, can be predicted. There can be no assurance that any patents the Company may own or control or license now and, in the future, will afford the Company commercially significant protection of its intellectual property or its projects or have commercial application. While the Company is not aware of any third party interests in its intellectual property rights and has taken steps to protect and confirm its interest in these rights, there is always a risk of third parties claiming involvement in technological and medical discoveries and if any such disputes arise, they could adversely affect the Company.</p>
ASX Compliance	<p>Re- Shareholders should note that any future investment by the Company in medical cannabis will be reviewed by ASX and the Company may be required to re-comply with chapters 1 and 2 of the ASX Listing Rules and there may be necessary escrow implications for the Shares offered under this entitlement issue.</p>
COVID-19	<p>The outbreak of the coronavirus disease (COVID-19) is impacting global economic markets. The nature and extent of the effect of the outbreak on the performance of the Company remains unknown. The Company's Share price may be adversely affected in the short to medium term by the economic uncertainty caused by COVID-19. Further, any governmental or industry measures taken in response to COVID-19 may adversely impact the Company's operations and are likely to be beyond the control of the Company.</p> <p>The Directors are monitoring the situation closely and have considered the impact of COVID-19 on the Company's business and financial performance. However, the situation is continually evolving, and the consequences are therefore inevitably uncertain. In compliance with its continuous disclosure obligations, the Company will continue to update the market in regard to the impact of COVID-19 on its revenue channels and any adverse impact on the Company.</p>
Loans and company specific investments	<p>The 31 December 2021 Half Year Report further indicates a material uncertainty that may affect the ability of Advent to realise the carrying value of the exploration assets in the ordinary course of business and may affect the ability of the Company to realise the carrying value of its \$4,250,000 investment and its loan receivable in Advent in the ordinary course of business.</p> <p>As at 30 June 2022 the Company is owed \$4,137,588 by Advent, of which \$3,020,000 has been lent on normal commercial terms for the purposes of Advent's subsidiary Aotearoa Offshore Ltd NZ acquiring a 30% Participating interest in Petroleum Exploration Permits from OMV New Zealand. This loan is to be utilised for the purpose of Advent making payment of the back-costs and to cover approved budgeted Work Programme costs for 2022 as set out in a Farm Out Agreement with OMV New Zealand. This loan is to be paid back to the Company within 24 months after the date it was issued.</p>

Risk	Description
	<p>In relation to the Company's investment in Advent, on 16 December 2021, the Company permit participants Advent and Bounty Oil and Gas (ASX: BUY) received a notification of refusal from the National Offshore Petroleum Title Authority (NOPTA) of the joint venture's applications to extend the PEP 11 Permit for gas exploration in the offshore Sydney Basin lodged in January 2021. Advent has an 85% interest in the PEP 11 Permit through its 100% subsidiary Asset Energy Pty Ltd. On 2 June 2022, the Company announced that Advent, through Asset Energy has applied to the Federal Court pursuant to section 5 of the Administrative Decisions (Judicial Review) Act 1977 (Cth) and section 39B of the Judiciary Act 1903 (Cth) for a review of the decision.</p> <p>The above conditions indicate a material uncertainty that may affect the ability of Advent to realise the carrying value of the exploration assets in the ordinary course of business and may affect the ability of the Company to realise the carrying value of its loan receivable and its investment in Advent in the ordinary course of business.</p> <p>The funds raised under the Offer are considered sufficient to meet the current proposed objectives of the Company. Additional funding may be required in the event future costs exceed the Company's estimates and to effectively implement its business and operations plans in the future, to take advantage of opportunities for acquisitions, joint ventures, or other business opportunities, and to meet any unanticipated liabilities or expenses which the Company may incur.</p> <p>The Company may seek to raise further funds through equity or debt financing, joint ventures, or other means. There can be no assurance that additional finance will be available when needed or, if available, the terms of the financing might not be favourable to the Company and might involve substantial dilution to Shareholders.</p>
<p>Advent Farm Out Agreement</p>	<p>The Company announced on 4 April 2022 that Advent, through its subsidiary Aotearoa Offshore Ltd NZ, has the right to acquire a 30% participating interest in Petroleum Exploration Permits covering a 5,180km² area in Taranaki Basin from OMV New Zealand Limited.</p> <p>As mentioned above, the Company has a 36.1% interest in Advent and has provided Advent loan funding of \$3,020,000 to cover expenditure on the Petroleum Licences and to cover an agreed work programme and budget expenditures for the farm out. This loan means that Advent has sufficient funds for all of its 2022 commitments. The loan of \$3,020,000 provided by the Company to Advent is refundable to the Company in the event New Zealand Government approval is not received.</p> <p>As at the date of this Prospectus, Aotearoa Offshore has been assigned its 30% participating interest and there has been an extension of time for the joint venture parties to satisfy the conditions precedent, which include obtaining any necessary government approvals and consents. Further, the expenditure on the licences is at an early stage of exploration, and potential investors should understand that mineral exploration and development are high-risk undertakings. The required ongoing expenditures may not result in exploration success from the discovery of an economic oil and gas deposit. Even if an apparently viable deposit is identified, there is no guarantee that it can be economically exploited.</p> <p>Aotearoa is not the registered owner of the licenses and therefore the Aotearoa's ability to achieve its objectives in respect of the licenses is dependent upon it and the registered holder of the licenses complying with their obligations under the relevant agreements giving rise to the Aotearoa interest, and on the registered holder complying with the terms and conditions of the licenses and any other applicable legislation.</p> <p>Any failure to comply with these obligations may result in the Aotearoa losing its interest in those licenses, which may have a material adverse effect on Advent's operations, the Company's investment in Advent and recovery of its loan from Advent, which may also affect the performance and value of the Company's Shares.</p>

Risk	Description
	The Company has no current reason to believe that the registered owners of the Petroleum Licences will not meet and satisfy their respective obligations under the relevant agreements and other applicable legislation.
Shares Trading below exercise price of New Options	The price of the Company's Shares trading on ASX may be significantly lower than the exercise price of the New Options and the Placement Options. Should the Share price not trade at or above the exercise price of the Options, the Options will not have any real value.

5.3 Industry specific

Risk	Description
Research and development	The Company can make no representation that any of its research into or development of the technologies will be successful, that the development milestones will be achieved, or that the Technologies will be developed into products that are commercially exploitable
Oil and gas industry risks	<p>The Company has a 36.1% interest in Advent Energy Ltd (Advent). Risks associated with this significant investment include but are not limited to risks associated with failure to discover an economic reserve or successfully produce from a reserve, fluctuations in oil and gas prices, no guarantee of permit renewals or granting of production licences, all of which could have a material adverse effect on the Company's investment.</p> <p>(a) Illiquid investment: as Advent is an unlisted entity, there is a risk that there will not be a ready market for the Company to sell its Advent Energy shares.</p> <p>(b) Oil and gas exploration: the business of oil and gas exploration, project development and production, by its nature, contains elements of significant risk with no guarantee of success. A failure to discover an economic reserve, or to successfully produce from such a reserve, will adversely affect Advent Energy's performance and have a resulting effect on the value of the Company's investment in Advent Energy.</p> <p>(c) Oil and gas price volatility: The demand for, and price of, oil and natural gas is highly dependent on a variety of factors, including international supply and demand, the level of consumer product demand, weather conditions, the price and availability of alternative fuels, actions taken by governments and international cartels, and global economic and political developments.</p> <p>International oil and gas prices have fluctuated widely in recent years and may continue to fluctuate significantly in the future. Fluctuations in oil and gas prices and, in particular, a material decline in the price of oil or gas may have a material adverse effect on the Advent's business, financial condition and results of operations.</p> <p>(d) Exploration and production licences: Advent's operations are dependent upon the grant of appropriate licences, concessions, leases, permits and regulatory consents, which may be withdrawn or made subject to limitations. There is no guarantee that, upon completion of any exploration, a production licence will be granted with respect to exploration territory. There can also be no assurance that any exploration permit will be renewed or if so, on what terms.</p> <p>These licences place a range of past, current and future obligations on Advent. In some cases, there could be adverse consequences for breach of these obligations, ranging from penalties to, in extreme cases, suspension or</p>

- termination of the relevant licence or related contract. These may then affect the Company's investment in Advent Energy.
- (e) **Expansion targets and operational delays:** There can be no assurance that Advent will be able to complete any development of its properties on time or to budget, or that the current personnel, systems, procedures and controls will be adequate to support Advent's operations. Any failure of management to identify problems at an early stage could have an adverse impact on Advent's financial performance.
- (f) **Resources, reserves and production:** The figures for oil & gas reserves and resources presented in this Prospectus where given are estimates and no assurance can be given that the anticipated figures will be achieved or that the indicated level of recovery will be realised. Market fluctuations in the price of oil & gas may render oil & gas reserves and resources uneconomical. Moreover, short-term operating factors relating to oil & gas reserves and resources, such as the need for orderly development of an oil & gas reservoir may cause an oil & gas operation to be unprofitable in any particular accounting period.
- (g) **Limited operating history:** Advent may not have assets producing positive cash flow and its ultimate success may depend on its ability to generate cash flow from active oil & gas operations in the future and its ability to access equity markets for its development requirements. Advent has not made profits to date and there is no assurance that it will do so in the future. A portion of Advent's activities will be directed to the search for and the development of new oil & gas deposits. Significant capital investment will be required to achieve commercial production from Advent's existing projects and from successful exploration efforts. There is no assurance that Advent will be able to raise the required funds to continue these activities.
- (h) **Additional financing:** Advent is required to fund its share of approved exploration expenditure on certain of the properties on which it has exploration rights, failing which Advent's exploration rights in the relevant property may be either reduced or forfeited. Advent may acquire exploration rights in other exploration properties which may require acquisition payments to be made and exploration expenditures to be incurred. The only sources of funding currently available to Advent are through the issue of additional equity capital, project finance or borrowing. There is no assurance that Advent will be successful in raising sufficient funds to commence drilling or production operations or to meet its obligations with respect to the exploration properties in which it has or may acquire exploration rights. The Directors currently believe that Advent's working capital will not be sufficient to fund operations. Advent Energy will therefore have to seek additional financing for operations at a later date.
- (i) **Regulatory approvals:** Advent's operations and the exploration agreements which it has entered into require approvals, licences and permits from various regulatory authorities, governmental and otherwise (including project specific governmental decrees). Such approvals, licences and permits are subject to change in various circumstances and further project specific governmental decrees and/or legislative enactments may be required. There can be no guarantee that Advent will be able to obtain or maintain all necessary approvals, licences and permits that may be required and/or that all project specific governmental decrees and/or required legislative enactments will be forthcoming to explore for oil & gas and develop the properties on which it has exploration rights, commence

	<p>construction or operation of production facilities or to maintain continued operations that economically justify the costs involved.</p> <p>(j) Environmental factors: Advent's operations are subject to environmental regulation (including regular environmental impact assessments and the requirement to obtain and maintain certain permits) in all the jurisdictions in which it operates. Such regulation covers a wide variety of matters, including, without limitation, prevention of waste, pollution and protection of the environment, labour regulations and health and safety. Advent may also be subject under such regulations to clean-up costs and liability for toxic or hazardous substances which may exist on or under any of its properties or which may be produced as a result of its operations. Environmental legislation and permitting requirements are likely to evolve in a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their directors and employees.</p> <p>(k) Competition: The oil & gas exploration and production business is competitive in all of its phases. Advent competes with numerous other companies and individuals, including competitors with greater financial, technical and other resources than itself, in the search for and acquisition of exploration and development rights on attractive oil & gas properties. Advent's ability to acquire exploration and development rights on properties in the future will depend not only on its ability to develop the properties on which it currently has exploration and development rights, but also on its ability to select and acquire exploration and development rights on suitable properties for exploration and development. There is no assurance that Advent will continue to be able to compete successfully with its competitors in acquiring exploration and development rights on such properties.</p> <p>(l) Currency risk: Currency fluctuations may affect the cash flow that Advent hopes to realise from its operations, as oil & gas is sold and traded on the world markets in United States dollars. Advent's costs are incurred primarily in Australian dollars and United States dollars.</p> <p>(m) Uninsured risks: Advent Energy, as a participant in exploration and mining programmes, may become subject to liability for hazards that cannot be insured against or against which it may elect not to be so insured because of high premium costs. Advent Energy may incur a liability to third parties (in excess of any insurance cover) arising from pollution or other damage or injury.</p> <p>(n) Market perception: Market perception of small oil & gas exploration companies may change and this could impact on the value of the Company's holdings and impact on Advent's ability to raise further equity capital.</p>
Regulatory risk	The introduction of new legislation or amendments to existing legislation by governments, developments in existing common law, or the respective interpretation of the legal requirements in any of the legal jurisdictions which govern the Company's operations or contractual obligations, could impact adversely on the assets, operations and, ultimately, the Company's financial performance and its Securities. In addition, there is a commercial risk that legal action may be taken against the Company in relation to commercial matters.
Development and commercialisation of technologies	Securing rights to technologies, and in particular patents, is an integral part of securing potential product value in the outcomes of biotechnology research and development. Competition in retaining

	<p>and sustaining protection of technologies and the complex nature of technologies can lead to expensive and lengthy patents disputes for which there can be no guaranteed outcome.</p> <p>The granting of a patent does not guarantee that the rights of others are not infringed or that competitors will not develop competing technologies that circumvents such patents. The Company's success depends, in part, on its ability to obtain patents, maintain trade secret protection and operate without infringing the proprietary rights of third parties. Because the patent position of biotechnology companies can be highly uncertain and frequently involve complex legal and scientific evaluation, neither the breadth of claims allowed in biotechnology patents nor their enforceability can be predicted. There can be no assurance that any patents the Company or Universities may own or control or licence now and in the future will afford the Company commercially significant protection of the technologies, or that any of the projects that may arise from the technologies will have commercial applications.</p> <p>Although the Company is not aware of any third party interests in relation to the technologies rights of the technologies, and has taken steps to protect and confirm its interest in these rights, there is always a risk of third parties claiming involvement in technological and medical discoveries, and if any disputes arise, they could adversely affect the Company.</p> <p>Although the Company will implement all reasonable endeavours to protect its technologies, there can be no assurance that these measures have been or will be sufficient.</p>
Potential Acquisitions	As part of its business strategy, the Company may make acquisitions of or significant investments in complementary companies, products or technologies. Any such future transactions would be accompanied by the risks commonly encountered in making acquisitions of companies, products and technologies.
Climate Change Risks	Transitioning to a lower-carbon economy may entail extensive policy, legal, technology and market changes to address mitigation and adaption requirements related to climate change. Depending on the nature, speed and focus of these changes, transition risks may pose varying levels of financial and reputational risk to the Company. While the Company will endeavour to manage these risks and limit any consequential impacts, there can be no guarantee that the Company will not be impacted by these occurrences.
Negative publicity may adversely affect the Share price	Any negative publicity or announcement relating to any of the Company's substantial Shareholders, key personnel or activities may adversely affect the stock performance of the Company, whether or not this is justifiable. Examples of such negative publicity or announcements may include involvement in legal or insolvency proceedings, failed attempts in takeovers, joint ventures or other business transactions. No such issues are currently known to affect the Company.
Environment	The Company's operations are not regulated by any significant environmental regulation under the law of the Commonwealth or any State or Territory.

5.4 General risks

Risk	Description
Economic conditions and other global or national issues	<p>General economic conditions, movements in interest and inflation rates and currency exchange rates may have an adverse effect on the Company's exploration, development, and production activities, as well as on its ability to fund those activities.</p> <p>Factors such as fluctuations in currencies, commodity prices, inflation, interest rates, national and international political circumstances</p>

	(including outbreaks in international hostilities, wars, terrorist acts, sabotage, subversive activities, security operations, labour unrest, civil disorder, and states of emergency), natural disasters (including fires, earthquakes and floods), and quarantine restrictions, epidemics and pandemics may have an impact on the Company's exploration, development and production activities, as well as on its ability to fund those activities. The Company's future possible revenues and Share price can be affected by these factors, all of which are beyond the control of the Company or its Directors.
Commodity price volatility and exchange rate	If the Company achieves success leading to mineral production, the revenue it will derive through the sale of commodities exposes the potential income of the Company to commodity price and exchange rate risks. Commodity prices fluctuate and are affected by many factors beyond the control of the Company. Such factors include supply and demand fluctuations for precious and base metals, technological advancements, forward selling activities and other macro-economic factors.
Changes in government policy and legislation	Any material adverse changes in relevant government policies or legislation of Australia may affect the viability and profitability of the Company, and consequent returns to investors. The activities of the Company are subject to various federal, state and local laws governing prospecting, development, production, taxes, labour standards and occupational health and safety, and other matters.
Ukraine Conflict	<p>The current conflict between Ukraine and Russia (Ukraine Conflict) is impacting global economies and financial markets. The nature and extent of the effect the Ukraine Conflict may have on the Company's operations remains uncertain at this time. In the short to medium term, the Company's Share price may be adversely affected by the economic uncertainty caused by the Ukraine Conflict and the wider effect the conflict has on global economies and financial markets.</p> <p>The Directors are monitoring the potential secondary and tertiary macroeconomic impacts of the Ukraine Conflict, including the fluctuations in commodity and energy prices and the potential risk of cyber activity impacting governments and businesses. Further, any governmental or industry measures taken in response to the Ukraine Conflict, including limitations on travel and changes to import/export restrictions and arrangements involving Russia, may adversely impact the Company's operations and are likely to be beyond the control of the Company.</p> <p>The Company is monitoring the situation closely and considers the impact of the Ukraine Conflict on the Company's business and financial performance to, at this stage, be limited. However, the situation is continually evolving, and the consequences are therefore inevitably uncertain.</p>
Reliance on key management and personnel	The Company is dependent on its management, the loss of whose services could materially and adversely affect the Company and impede the achievements of its research and development objectives. Because of the specialised nature of the Company's business, its ability to commercialise its products and maintain its research programme will depend in part upon its ability to attract and retain suitably qualified management, scientists and research people over time. There can be no assurance that the Company will be able to attract or retain sufficiently qualified personnel on a timely basis, retain its key scientific and management personnel, or maintain its relationship with key scientific organisations.
Market conditions	Share market conditions may affect the value of the Company's quoted securities regardless of the Company's operating performance. Share market conditions are affected by many factors such as: <ul style="list-style-type: none"> (a) general economic outlook in both Australia and Internationally;

	<p>(b) introduction of tax reform or other new legislation, regulation or policy;</p> <p>(c) changes in exchange rates, interest rates and inflation rates;</p> <p>(d) changes in investor sentiment toward particular market sectors;</p> <p>(e) the demand for, and supply of, capital; and</p> <p>(f) the global security situation and the possibility of terrorist disturbances or other hostilities.</p> <p>Neither the Company nor the Directors warrant the future performance of the Company or any return on an investment in the Company.</p>
Insurance	Expenditure may need to be incurred that has not been taken into account in the preparation of this Prospectus. Although the Company is not aware of any such additional expenditure requirements, if such expenditure is subsequently incurred, this may adversely affect the expenditure proposals of the Company.
Dividends	Any future determination as to the payment of dividends by the Company will be at the discretion of the Directors and will depend on the financial condition of the Company, future capital requirements and general business and other factors considered relevant by the Directors. No assurance in relation to the payment of dividends or franking credits attaching to dividends can be given by the Company.
Litigation	<p>The Company is exposed to possible litigation risks including, but not limited to, intellectual property ownership disputes, contractual claims, environmental claims, occupational health and safety claims and employee claims. Further, the Company may be involved in disputes with other parties in the future which may result in litigation. Any such claim or dispute if proven, may impact adversely on the Company's operations, financial performance and financial position.</p> <p>Other than the Federal Court application applied for by Advent Energy, as mentioned above, the Company is not currently engaged in any litigation. The Company confirms that no person has applied for leave of the Court to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company. The Company was not a party to any such proceedings during the year.</p>
Unforeseen expenditure	Expenditure may need to be incurred that has not been taken into account in the preparation of this Prospectus. Although the Company is not aware of any such additional expenditure requirements, if such expenditure is subsequently incurred, this may adversely affect the expenditure proposals of the Company.

5.5 Investment speculative

The above list of risk factors ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company. The above factors, and others not specifically referred to above, may in the future materially affect the financial performance of the Company and the value of the New Options offered under this Prospectus.

Therefore, the New Options to be issued pursuant to this Prospectus carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those New Options.

Potential investors should consider that the investment in the Company is speculative and should consult their professional advisers before deciding whether to apply for New Options pursuant to this Prospectus.

6. ADDITIONAL INFORMATION

6.1 Litigation

As at the date of this Prospectus, the Company is not involved in any legal proceedings and the Directors are not aware of any legal proceedings pending or threatened against the Company.

6.2 Continuous Disclosure Obligations

The Company is a “disclosing entity” (as defined in Section 111AC of the Corporations Act) for the purposes of Section 713 of the Corporations Act and, as such, is subject to regular reporting and disclosure obligations. Specifically, like all listed companies, the Company is required to continuously disclose any information it has to the market which a reasonable person would expect to have a material effect on the price or the value of the Company’s securities.

This Prospectus is a “transaction specific prospectus”. In general terms a “transaction specific prospectus” is only required to contain information in relation to the effect of the issue of securities on the Company and the rights attaching to the securities. It is not necessary to include general information in relation to all of the assets and liabilities, financial position, profits and losses or prospects of the issuing company.

This Prospectus is intended to be read in conjunction with the publicly available information in relation to the Company which has been notified to ASX and does not include all of the information that would be included in a prospectus for an initial public offering of securities in an entity that is not already listed on a stock exchange. Investors should therefore have regard to the other publicly available information in relation to the Company before making a decision whether or not to invest.

Having taken such precautions and having made such enquires as are reasonable, the Company believes that it has complied with the general and specific requirements of ASX as applicable from time to time throughout the 3 months before the issue of this Prospectus which required the Company to notify ASX of information about specified events or matters as they arise for the purpose of ASX making that information available to the stock market conducted by ASX.

Information that is already in the public domain has not been reported in this Prospectus other than that which is considered necessary to make this Prospectus complete.

The Company, as a disclosing entity under the Corporations Act, states that:

- (a) it is subject to regular reporting and disclosure obligations;
- (b) copies of documents lodged with the ASIC in relation to the Company (not being documents referred to in Section 1274(2)(a) of the Corporations Act) may be obtained from, or inspected at, the offices of the ASIC; and
- (c) it will provide a copy of each of the following documents, free of charge, to any person on request between the date of issue of this Prospectus and the Closing Date:
 - (i) the annual financial report most recently lodged by the Company with the ASIC;

- (ii) any half-year financial report lodged by the Company with the ASIC after the lodgement of the annual financial report referred to in (i) and before the lodgement of this Prospectus with the ASIC; and
- (iii) any continuous disclosure documents given by the Company to ASX in accordance with the ASX Listing Rules as referred to in Section 674(1) of the Corporations Act after the lodgement of the annual financial report referred to in (i) and before the lodgement of this Prospectus with the ASIC.

Copies of all documents lodged with the ASIC in relation to the Company can be inspected at the registered office of the Company during normal office hours.

Details of documents lodged with ASX since the date of lodgement of the Company's latest annual financial report and before the lodgement of this Prospectus with the ASIC are set out in the table below.

Date	Description of Announcement
24 August 2022	Appendix 3B
24 August 2022	Cancel Proposed Issue of Securities Appendix 3B
24 August 2022	Correction of Dates to Rights Issue
23 August 2022	BPH PEP11 Strategy Update
23 August 2022	Pause in Trading
19 August 2022	Correction of Date in Capital Raising Announcement
18 August 2022	Reinstatement to Official Quotation
18 August 2022	Appendix 3B
18 August 2022	Appendix 3B
18 August 2022	Appendix 3B
18 August 2022	BPH raises up to \$1.9m in Placement and Rights Issue
17 August 2022	Suspension from Official Quotation
16 August 2022	Option expiry
15 August 2022	Trading Halt opens
11 August 2022	USA Patent granted for BPH investee Cortical
2 August 2022	Hydrogen Technology Investment settled
1 August 2022	Quarterly Activities/Appendix 4C Cash Flow Report
21 July 2022	Investee Advent Farm Out Extension of Time to Satisfy CPs
22 June 2022	Results of Meeting
2 June 2022	Investee Advent Energy Appeal re PEP 11 Permit Extension
24 May 2022	Proxy Form
24 May 2022	Reinstatement to Official Quotation
24 May 2022	Notice of General Meeting/Proxy Form
24 May 2022	Proposed Hydrogen Investment
19 May 2022	Update - Patagonia Genetics

Date	Description of Announcement
17 May 2022	Voluntary Suspension Update
12 May 2022	Investee Cortical Dynamics Grant Funding and Update
10 May 2022	Voluntary Suspension Update
3 May 2022	Voluntary Suspension Update
2 May 2022	Quarterly Activities/Appendix 4C Cash Flow Report
26 April 2022	Voluntary Suspension - Update
20 April 2022	Appendix 2A
20 April 2022	Amended 31 December 2021 Half year Financial Report
19 April 2022	Voluntary Suspension Update
12 April 2022	Voluntary Suspension Update
4 April 2022	Voluntary Suspension Update
4 April 2022	Advent Farmout Agreement
30 March 2022	PEP11 update
30 March 2022	BUY: Pep-11 Update
28 March 2022	Voluntary Suspension Update
21 March 2022	Voluntary Suspension Update
15 March 2022	Voluntary Suspension Update
8 March 2022	Voluntary Suspension Update
1 March 2022	Voluntary Suspension Update
28 February 2022	Half Yearly Report and Accounts
22 February 2022	Voluntary Suspension Update
16 February 2022	Voluntary Suspension Update
8 February 2022	Voluntary Suspension Update
1 February 2022	Quarterly Activities/Appendix 4C Cash Flow Report
28 January 2022	Voluntary Suspension Update
21 January 2022	Voluntary Suspension Update
14 January 2022	Voluntary Suspension Update
13 January 2022	Voluntary Suspension Update
10 January 2022	Voluntary Suspension Update
29 December 2021	Voluntary Suspension Update
29 December 2021	Details of Company Address
24 December 2021	Voluntary Suspension Update
20 December 2021	Voluntary Suspension Update
16 December 2021	Investee Advent Energy PEP 11 Permit Extension not Granted
16 December 2021	BUY: PEP11 Refusal of Extension and Cerberus Update
14 December 2021	Investor Webinar
9 December 2021	Suspension from Official Quotation

Date	Description of Announcement
7 December 2021	Trading Halt
3 December 2021	Notification of cessation of securities - BPH
1 December 2021	Option Expiry
29 November 2021	Results of Meeting
29 November 2021	Chairman's Address to Shareholders
25 November 2021	Investee Advent Call for Tender Directional Drilling
22 November 2021	Investee Advent Call for Tender Drilling Fluids
17 November 2021	BPH Investment in Advent Energy

ASX maintains files containing publicly available information for all listed companies. The Company's file is available for inspection at ASX during normal office hours.

6.3 Market price of shares

The Company is a disclosing entity for the purposes of the Corporations Act and its Shares are enhanced disclosure securities quoted on ASX.

The highest, lowest and last market sale prices of the Shares on ASX during the three months immediately preceding the date of lodgement of this Prospectus with the ASIC and the most recent respective dates of those sales were:

	(\$)	Date
Highest	\$0.062	24 August 2022
Lowest	\$0.01	27 June 2022, 29 June 2022, 30 June 2022
Last	\$0.028	26 August 2022

6.4 Material contracts

6.4.1 Lead Manager Mandate

The Company has appointed EverBlu Capital to act as lead manager of the Offer (**Lead Manager Mandate**), the material terms and conditions of which are summarised below:

Fees	6% on funds raised by EverBlu in the Placement
Lead Manager Options	One (1) option for every three (3) Placement Shares issued (may be subject to shareholder approval; if approval not granted, then cash equivalent will be payable)
Term	The Company agrees that EverBlu will act in an exclusive capacity as Lead Manager on all capital raising activities for a period of 6 months from the date of signing this agreement.

The Lead Manager Mandate otherwise contains provisions considered standard for an agreement of its nature (including representations, warranties and confidentiality provisions).

6.5 Interests of Directors

Other than as set out in this Prospectus, no Director or proposed director holds, or has held within the 2 years preceding lodgement of this Prospectus with the ASIC, any interest in:

- (a) the formation or promotion of the Company;
- (b) any property acquired or proposed to be acquired by the Company in connection with:
 - (i) its formation or promotion; or
 - (ii) the Offer; or
- (c) the Offer,

and no amounts have been paid or agreed to be paid and no benefits have been given or agreed to be given to a Director or proposed director:

- (d) as an inducement to become, or to qualify as, a Director; or
- (e) for services provided in connection with:
 - (i) the formation or promotion of the Company; or
 - (i) the Offer.

Security holdings

The relevant interest of each of the Directors in the Securities as at the date of this Prospectus, together with their respective Entitlement, is set in Section 1.5.

Remuneration

The remuneration of an executive Director is decided by the Board, without the affected executive Director participating in that decision-making process. The total maximum remuneration of non-executive Directors is initially set by the Constitution and subsequent variation is by ordinary resolution of Shareholders in general meeting in accordance with the Constitution, the Corporations Act and the ASX Listing Rules, as applicable. The determination of non-executive Directors' remuneration within that maximum will be made by the Board having regard to the inputs and value to the Company of the respective contributions by each non-executive Director. The current amount has been set at an amount not to exceed \$250,000 per annum.

A Director may be paid fees or other amounts (i.e. non-cash performance incentives such as Options, subject to any necessary Shareholder approval) as the other Directors determine where a Director performs special duties or otherwise performs services outside the scope of the ordinary duties of a Director. In addition, Directors are also entitled to be paid reasonable travelling, hotel and other expenses incurred by them respectively in or about the performance of their duties as Directors.

The following table shows the total (and proposed) annual remuneration paid to both executive and non-executive Directors as disclosed in the Company's 2021 Annual Report.

Director	Financial year ending 30 June 2021 \$	Financial year ending 30 June 2022 \$	Proposed financial year ending 30 June 2023 \$
David Breeze			
Shares ²	431,722 ¹	Nil	Nil
Options	157,452 ¹	Nil	Nil
Salary	\$148,000	\$148,000	\$148,000
Tony Huston			
Shares ²	48,834	Nil	Nil
Options	18,593	Nil	Nil
Salary	\$30,000	\$40,000	\$25,000
Charles Maling			
Shares ²	55,082	Nil	Nil
Options	19,402	Nil	Nil
Salary	25,000	\$25,000	\$25,000

Notes:

1. Comprising securities issued to Grandbridge Limited, a company of which Mr Breeze is the Managing Director.
2. The issue of these Shares to the Directors of the Company (or their nominees) included one (1) free-attaching Option for every two (2) Shares issued with an exercise price of \$0.05 per Option and an expiry date of 29 July 2022. The Options expired on 29 July 2022 without being exercised by the Directors.

6.6 Interests of Experts and Advisers

Other than as set out below or elsewhere in this Prospectus, no:

- (a) person named in this Prospectus as performing a function in a professional, advisory or other capacity in connection with the preparation or distribution of this Prospectus;
- (b) promoter of the Company; or
- (c) underwriter (but not a sub-underwriter) to the issue or a financial services licensee named in this Prospectus as a financial services licensee involved in the issue,

holds, or has held within the 2 years preceding lodgement of this Prospectus with the ASIC, any interest in:

- (d) the formation or promotion of the Company;
- (e) any property acquired or proposed to be acquired by the Company in connection with:
 - (i) its formation or promotion; or
 - (ii) the Offer; or
- (f) the Offer,

and no amounts have been paid or agreed to be paid and no benefits have been given or agreed to be given to any of these persons for services provided in connection with:

- (g) the formation or promotion of the Company; or
- (h) the Offer.

Steinepreis Paganin has acted as the solicitors to the Company in relation to the Offer. The Company estimates it will pay Steinepreis Paganin \$15,000 (excluding GST and disbursements) for these services. During the 24 months preceding lodgement of this Prospectus with the ASIC, Steinepreis Paganin has been paid fees totalling \$145,649 (excluding GST and disbursements) for legal services provided to the Company.

EverBlu Capital will be paid a 6% cash fee of approximately \$90,000 (excluding GST) in respect of the Placement. During the 24 months preceding lodgement of this Prospectus with the ASIC, the Company has paid EverBlu capital approximately \$420,000 (excluding GST) in fees for services provided.

6.7 Consents

Chapter 6D of the Corporations Act imposes a liability regime on the Company (as the offeror of the securities), the Directors, the persons named in the Prospectus with their consent as Proposed Directors, any underwriters, persons named in the Prospectus with their consent having made a statement in the Prospectus and persons involved in a contravention in relation to the Prospectus, with regard to misleading and deceptive statements made in the Prospectus. Although the Company bears primary responsibility for the Prospectus, the other parties involved in the preparation of the Prospectus can also be responsible for certain statements made in it.

Each of the parties referred to in this Section:

- (a) does not make, or purport to make, any statement in this Prospectus other than those referred to in this Section;
- (b) in light of the above, only to the maximum extent permitted by law, expressly disclaim and take no responsibility for any part of this Prospectus other than a reference to its name and a statement included in this Prospectus with the consent of that party as specified in this Section; and
- (c) has not withdrawn its consent prior to the lodgement of this Prospectus with the ASIC.

EverBlu Capital has given its written consent to being named as the Lead Manager to the Offer in this Prospectus.

Steinepreis Paganin has given its written consent to being named as the solicitors to the Company in this Prospectus.

6.8 Expenses of the offer

In the event that all Entitlements are accepted, the total expenses of the Entitlement Offer and the Placement are estimated to be approximately \$148,238 (excluding GST) and are expected to be applied towards the items set out in the table below:

	\$
ASIC fees	3,206
ASX fees	23,532
Legal fees	15,000
Broker management fee	90,000
Printing and distribution	15,000
Miscellaneous	1,500
Total	148,238

7. DIRECTORS' AUTHORISATION

This Prospectus is issued by the Company and its issue has been authorised by a resolution of the Directors and Proposed Directors.

In accordance with section 720 of the Corporations Act, each Director and Proposed Director has consented, and as at the date of this Prospectus has not withdrawn his consent, to the lodgement of this Prospectus with the ASIC.



David Breeze
Chairman and Company Secretary
Signed for and on behalf of
BPH Energy Limited

8. DEFINITIONS

\$ means Australian dollars.

Applicant means an investor who applies for Shares pursuant to the Offer.

Application means an application for Shares made on an Application Form.

Application Form means an application form either attached to or accompanying this Prospectus.

ASIC means the Australian Securities and Investments Commission.

ASX means ASX Limited (ACN 008 624 691) or the financial market operated by it as the context requires.

ASX Listing Rules means the Listing Rules of the ASX.

ASX Settlement Operating Rules means the settlement rules of the securities clearing house which operates CHESS.

Board means the board of Directors unless the context indicates otherwise.

Business Day means Monday to Friday inclusive, except New Year's Day, Good Friday, Easter Monday, Christmas Day, Boxing Day and any other day that ASX declares is not a Business Day.

Closing Date means the closing date specified in Section 3 of this Prospectus (unless extended or closed earlier).

Company means BPH Energy Limited (ACN 095 912 002).

Constitution means the constitution of the Company as at the date of this Prospectus.

Corporations Act means the *Corporations Act 2001* (Cth).

Directors means the directors of the Company as at the date of this Prospectus.

Entitlement means the entitlement of a Shareholder who is eligible to participate in the Offer.

Entitlement and Acceptance Form means the entitlement and acceptance form either attached to or accompanying this Prospectus.

Ineligible Shareholder means a Shareholder as at the Record Date whose registered address is not situated in Australia or New Zealand.

Lead Manager means EverBlu Capital as set out in Section 6.4.1.

New Option means an Option issued under the Entitlement Offer on the terms set out in Section 4.2.

Offer means the Entitlement Offer as set out in Section 1.3 and 2.1.

Official Quotation means official quotation on ASX.

Opening Date means the opening date specified in Section 3 of this Prospectus.

Option means an option to acquire a Share.

Optionholder means a holder of an Option.

Placement means the Placement undertaken by the Company as set out in Section 1.3.

Placement Option means an Option issued to Placement participants as set out in Section 1.3 and 2.2.2, and on the terms set out in Section 4.2.

Prospectus means this prospectus.

Record Date means the date specified in the timetable set out at the commencement of this Prospectus.

Section means a section of this Prospectus.

Securities means Shares and/or Options as the context requires.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means the holder of a Share.

Shortfall means the Securities not applied for under the Offer (if any).

Shortfall Application Form means the Shortfall Offer application form either attached to or accompanying this Prospectus.

Shortfall Offer means the offer of the Shortfall Securities on the terms and conditions set out in Section 2.7.

Shortfall Securities means those Securities not applied for under the Offer (if any) and offered pursuant to the Shortfall Offer.

WST means Western Standard Time as observed in Perth, Western Australia.